natgillin/translations-raw huggingface dataset:
50 mg of blended tobacco was loosely placed against the substrate granules. 
50 mg mješanog duhana labavo se postavi naspram granula supstrata.
(European Patent Application Publication No. 
Broj europske prijave patenta: EP 08714211.3
The polymer composition according to claim 31 or 32, wherein the polymer composition is a masterbatch, preferably the masterbatch comprises the surface treated filler material product in an amount of from 50 to 85 wt.-%, preferably from 60 to 85 wt.-% and more preferably from 70 to 80 wt.-%, based on the total weight of the masterbatch. 
Polimerni pripravak prema zahtjevu 27 ili 28, naznačen time da polimerni pripravak je glavna šarža, pri čemu glavna šarža sadrži proizvod površinski obrađenog materijala punila u količini od 50 do 85 tež.-%, poželjno od 60 do 85 tež.-% i poželjnije od 70 do 80 tež.-%, u odnosu na ukupnu težinu glavne šarže.
providing the cell of claim 17, and culturing the cell under conditions that permit expression of the nucleic acid. 
dobivanje stanice prema zahtjevu 24, i uzgoj stanične kulture pod uvjetima koji omogućuju ekspresiju nukleinske kiseline.
A catheter securement device adapted to be adhesively mounted to the skin of a patient to secure a catheter comprising a distal tube member, said device comprising: 
Uređaj za osiguravanje katetera (10) prilagođen da bude ljepljivo montiran na kožu pacijenta da se osigura kateter koji sadrži član distalne cijevi, navedeni uređaj sadrži:
A process for gasification of organic solid materials in a fluidised bed reactor (1) with a cylindrical body and a bottom (2) with an inverted frustoconical section by means of a circulating gas flow containing solid fluidised material particles, characterised in that it comprises: 
Postupak rasplinjavanja organskih čvrstih materijala u reaktoru s fluidiziranim slojem (1) cirkuliranjem struje plina koja sadrži čestice čvrstog fluidiziranog materijala, koji se sastoji u:
with said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: 
HR P20131047 T1 PATENTNI ZAHTJEVI Farmaceutska kompozicija, koja sadrži jednu ili više komponenti izabranih iz grupe koju čine:
In accordance with an embodiment, said hull insert, or trunk 2, is a structure integrated into the structure of the hull 4 that does not need, to define said watertight walls, a separate cell added to an interspace obtained in the hull. 
10. Sklop (1) sukladno bilo kojem od prethodnih zahtjeva, pri čemu je umetak za trup, ili sanduk (2), struktura integrirana u strukturu trupa (4).
coupling a compound of formula (XVIII): or an acid addition salt thereof, with a compound of formula (XIX): wherein: 
BAE (XVIII) ili njegova kisela adicijska sol; (6) spajanje spoja formule (XVIII) sa spojm formule (XIX);
RD1 is attached to carbon 3" or 4"; 
R'' je vezan na ugljik broj 3" ili 4";
a motor (12) for controlling the transfer of the extraction module between the closed and opened state, and 
- < motor (12) za upravljanje s premještanjem modula za ekstrakciju između zatvorenog i otvorenog položaja, i
The compound according to Claim 1 or a pharmacologically acceptable salt thereof, which is 6-(1-((6-Cyclopropyl-2,4'-difluoro-3-isopropoxybiphenyl-4-yl)methyl)piperidin-4-yl)-2-ethyl-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid or a pharmacologically acceptable salt thereof. 
Spoj prema zahtjevu 1 ibi njegova farmakološki prihvatljiva sol, naznačen/a time, Ga je to 6-(1-((6-ciklopropilkarboksilna kiselina ili njezina farmakološki prihvatljiva sol.
A method according to any one of 28 to 30 wherein the disorder mediated by inappropriate PI3-kinase activity is COPD. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je poremećaj uzrokovan neodgovarajućom aktivnošću PI3-kinaze COPD.
The method of claim 1 including heating dilution water and directing the heated dilution water into the hydrolyzed sludge to heat the hydrolyzed sludge. 
Postupak prema bilo kojem od patentnih zahtjeva 1-3 naznačeno time da se zagrijava voda za razrjeđivanje 1 usmjerava zagrijana voda za razrjeđivanje u hidrolizirani mulj da bi se zagrijao hidrolizirani mulj.
The expression vector according to claim 7, comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:s 84 to 88 and their conservative sequence variants. 
Ekspresijski vektor prema zahtjevu 7, koji sadrži sekvencu nukleotida izabranu iz skupine koja se sastoji od SEQ ID NO:s 84 do 88 1 njihovih konzervativnih varijanta sekvenci.
-X-Y- together represents a group of the formula: wherein: 
-X-Y- zajedno predstavlja skupinu formule:
In further addition, the present invention relates to a method for treating, preventing or ameliorating (hyper)proliferative diseases and/or disorders responsive to induction of apoptosis, such as e.g. benign or malignant neoplasia, e.g. cancer, particularly any of those cancer diseases mentioned herein, in a patient comprising administering separately, simultaneously, concurrently, sequentially or chronologically staggered to said patient in need thereof an amount of a first active compound, which is a compound according to the present invention, and an amount of at least one second active compound, said at least one second active compound being a standard therapeutic agent, particularly at least one art-known anti-cancer agent, such as e.g. one or more of those chemotherapeutic and target-specific anti-cancer agents mentioned herein, wherein the amounts of the first active compound and said second active compound result in a therapeutic effect. 
Sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što je namijenjena upotrebi u postupku liječenja, sprječavanja ili ublažavanja hiperproliferativnih bolesti i/ili poremećaja koji reagiraju na induciranje apoptoze, poput dobroćudnih ili zloćudnih novotvorina, primjerice raka, kod pacijenta, gdje se odvojeno, istodobno, paralelno, uzastopno ili kronološki razdijeljeno na navedenom pacijentu kojem je to potrebno primijenjuje količinu prvog aktivnog spoja, koji je sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, i količinu najmanje jednog drugog aktivnog spoja, gdje je navedeni drugi aktivni spoj sredstvo protiv raka, kojeg se bira iz skupine koju čine kemoterapijska sredstva protiv raka i ciljno specifična sredstva protiv raka, gdje količine prvog aktivnog spoja i navedenog drugog aktivnog spoja rezultiraju terapijskim učinkom.
Therefore, the suction cups 8, 9 and the gripper 10 are moved by hypocycloid movement, traveling from the area where the pouches 102 and spouts 103 are picked up from their magazines 2, 3 to the area where the pouches and spouts are transferred to and released to the rotary machine for the processing of the pouches and spouts, indicated as R in FIG. 
Na taj način se usisne čašice 8, 9 i naprava za hvatanje 10 kreću hipocikloidnim kretanjem, putujući od prostora gdje se uzimaju vrećice 102 1 kljunovi 103 iz spremišta 2, 3 prema prostoru gdje se vrećice 1 kljunovi prenose na rotacijski stroj za obradu istih (označeno slovom R na slici 2).
The LNG fuel tank system according to claim 1, wherein a compressor which is situated in a suction and compression line extending between the LNG fuel tank and gas vessel is used as to limit the LNG fuel tank pressure during bunkering and pressure relieving the LNG fuel tank. 
Sustav spremnika za LNG gorivo prema bilo kojem prethodnom zahtjevu, naznačen time da se kompresor (5) koji je smješten u usisnom i tlačnom vodu (6, 7) proteže između spremnika za LNG gorivo (4) i posude za plin (8) koristi za ograničavanje pritiska u spremniku za LNG gorivo tijekom skladištenja i oslobađanje pritiska spremnika za LNG gorivo.
The material according to anyone of claims 1-17 wherein the whole composite is showing a water vapour diffusion barrier property of at least µ 2500, preferably at least µ 5000, especially preferred at least µ 10000, according to EN 12086. 
Materijal temeljem bilo kojeg od zahtjeva 1-17 naznačen time što čitav kompozit pokazuje svojstva barijere difuzije vodene pare od barem u 2500, poželjno barem u 5000, naročito poželjno barem u 10000, u skladu s EN 12086.
A chimeric peptide consisting of a first domain and a second domain directly linked by a covalent bond or linked by a linker sequence of 1 to 10 amino acids, the first domain comprising a trafficking sequence, and the second domain consisting of a c-Jun N-terminal (JNK) inhibitor sequence according to SEQ ID NO: 2 or a variant sequence of SEQ ID NO: 2 with 1, 2 or 3 amino acids deleted from either terminus of SEQ ID NO: 2, wherein the trafficking sequence comprises the amino acid sequence of SEQ ID NO: 6 or a sequence variant of SEQ ID NO: 6 with 1 or 2 amino acids deleted from either terminus of SEQ ID NO: 6, and wherein the trafficking sequence and the JNK inhibitor sequence are composed exclusively of D-enantiomeric amino acids and the linker sequence is composed of L amino acids, D amino acids or a combination of both. 
Kimerni peptid koji sadrži prvu domenu, drugu domenu i proizvoljno vezujuću sekvencu, te prva domena sadrži transportnu sekvencu i druga domena sadrži JNK inhibicijsku sekvencu, naznačen time da prva domena sadrži sve-D retro-inverzo sekvence amino kiseline u skladu sa SEQ ID NO:6 te time da druga domena sadrži sve-D retro-inverzo sekvence amino kiseline u skladu sa SEQ ID NO:2, pri čemu je prva domena vezana na C-terminalni kraj druge domene bilo izravno ili pomoću navedene vezujuće sekvence koja sadrži 1 do 10 amino kiselina.
w is an integer from 0 to 6; 
w je cijeli broj od 0 do 6;
individually displacing each stitch cam (7) in accordance with the relative corrective value, such as to reduce the difference between the respective yarn (9) consumption datum of the corresponding yarn feeder (8) and the reference value for yarn (9) consumption, in order to balance the fabric under production. 
- < individualno izmještanje svakog ekscentra očica (7) u suglasju s relativnom korektivnom vrijednosti, kako bi se smanjila razlika između datuma potrošnje prediva (9) odgovarajućeg opskrbljivača predivom (8) i referentne vrijednosti za potrošnju prediva (9) kako bi se balansiralo tkaninu u proizvodnji.
The use of claim 15 or the compound for use in a method of treatment of claim 16, wherein the Wnt-mediated disorder is keloids, fibrosis, proteinuria, kidney graft rejection, osteoarthritis, Parkinson's disease, cystoid macular edema, retinopathy, macular degeneration or a cell proliferative disorder associated with aberrant Wnt signaling activity. 
Uporaba prema zahtjevu 12, ili spoj ili njegova farmaceutski prihvatljiva sol za uporabu u postupku liječenja, prema zahtjevu 13, naznačen(a) time, da je poremećaj posredovan putem WNT, sljedeći: keloidi, fibroze, proteinurija, odbacivanje bubrežnih usadaka, osteoartritis, Parkinsonova bolest, cistoidni makularni edem, retinopatija, makularna degeneracija ili stanični proliferativni poremećaj povezan sa zastranjivanjem signalnog djelovanja WNT.
mg portions of the powder mixture from Example 1 were heated to 80° C. and in placed in the die of the tabletting tool. 
Smjesa praha iz Primjera 1 zagrijana je u obrocima po 300 mg na 80"C i napunjena u matricu alata za tabletiranje.
The liquefied gas treatment method according to claim 1, wherein, when the LNG stored in the cargo tank is supplied to the sub engine, a heavy hydrocarbon component is separated from the LNG so as to adjust a methane number of the LNG to a value necessary for the sub engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se plinovitu komponentu BOG-a, koji se dekomprimira u plinovito-tekuće miješano stanje prilikom prolaska kroz element za dekomprimiranje (22), pomiješa s BOG-om koji se ispušta iz spremnika za teret (1;11), te šalje u kompresor (150;13).
Instead of a CO2 cartridge it would also be possible to use a container containing active carbon as described in NL-A 1012922 in the name of the Applicant or an aerosol container known per se. 
Umjesto CO, patrone bilo bi moguće upotrijebiti i spremnik koji sadrži aktivni ugljen, kao što je opisano u NL-A 1012922, u ime Aplikanta, ili spremnik aerosola koji se sam po sebi razumije.
For these patients, antibiotics are typically provided in liquid forms, such as solutions, emulsions, and suspensions, which usually permit perceptible exposure of the antibiotic to the taste bud. 
Za te pacijente, antibiotici se uobičajeno pripremaju u tekućim oblicima poput otopina, emulzija i suspenzija što uobičajeno traži i odgovarajuće izlaganje antibiotika ispitivanju okusa.
contacting the composition with the biological sample; 
kontakt pripravka s biološkim uzorkom;
The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. 
Radionukleotidi koji su ugrađeni u instant radiološki označene spojeve će ovisiti o specifičnim primjenama radiološki označenih spojeva.
removing protecting group PG from said compound of formula Ib.1 to form VSN-16 
- uklanjanja zaštitne skupine PG s navedenog spoja formule Ib.1 kako bi se dobio VSN-16: o
Z is H, SR or -COR, wherein R is linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocycloalkyl radical. 
je SR ili -COR, gdje R je linearni alkil ili alkenil s 1 do 10 atoma ugljika, razgranati ili ciklički alkil ili alkenil s 3 do 10 atoma ugljika, ili jednostavan ili supstituirani aril ili heterociklički aromatski ili heterocikloalkilni radikal.
A lighting module of claim 1, wherein said microchip is configured to operate the switching device such that substantially 900 mA is delivered to the light emitting diode when said thermistor senses 25°C. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da je navedeni mikročip konfiguriran da upravlja preklopnim sklopom tako da se LED diodi isporučuje 900 mA kada navedeni termistor odčita temperaturu od 25
A wound dressing as claimed in any preceding claim wherein the open structure is knitted. 
Zavoj za rane prema bilo kojem od prethodnih zahtjeva naznačen time da je otvorena struktura pletena.
The pharmaceutical composition according to any one of the claims 1-3, wherein the release of the fumaric acid ester is as follows: within the first 6 hours after start of the test at the most about 95% w/w of the total amount of the fumaric acid ester contained in the composition is released. 
unutar prva 3 sata nakon početka ispitivanja oslobodi se najviše 70% w/w ukupne količine dimetilfumarata sadržanog u sastavu, i unutar prva 4 sata nakon početka ispitivanja oslobodi se najviše 92% w/w ukupne količine dimetilfumarata.
providing a capsular saccharide having at least one hydroxyl group on a monosaccharide unit; and 
(a) osiguravanja saharida kapsule koji ima najmanje jednu hidroksilnu skupinu na monosaharidnoj jedinici; i
In one specific embodiment, the compound is of the formula (VIb): 
Spoj patentnog zahtjeva 1 gdje spoj ima formulu (VIb):
the molecular weight of the HA is less than or about 50 kDa and the HA is in an amount of about 0.1%. 
molekularna masa HA iznosi manje ili približno 50 kDa, a količina HA iznosi približno 0,1% .
Conveyor according to claim 1 - 7, further comprising a third exit opposite to and below the input opening. 
Prema gore orijentirano skladište prema patentnom zahtjevu 21, koje dodatno sadrži treći izlaz nasuprot i ispod ulaznog otvora.
By using the more sterically demanding L-Selectride as the borohydride reducing agent rather than sodium borohydride, formation of the RRR and SSS isomers of dihydrotetrabenazine is minimised or suppressed. 
Uporabom sterički zahtjevnijeg "L-Selectride" kao borohidrid reducirajućeg sredstva radije nego li natrij borohidrida, formiranje RRR i SSS izomera dihidrotetrabenazina je minimalizirano ili potisnuto.
MMVF according to claim 13, wherein the MMVF have a composition comprising the following oxides, expressed by wt of oxides: 
MMVF sukladno patentnom zahtjevu 10 ili 11, naznačeno time da MMVF ima spoj koji sadrži slijedeće okside, izraženo eksprimiranom težinom oksida:
The method according to claim 1, wherein the concrete aggregate of the bulk material and the gas comprising carbon dioxide are left to react with one another so as to form reaction products at a temperature in a temperature range from 60 to less than 90° C. 
Postupak prema barem jednom od prethodnih zahtjeva, naznačen time, da se betonski kompozit iz gomile materijala (9) 1 plin koji sadrži ugljični dioksid, ostavljaju da međusobno reagiraju, tako da stvaraju reakcijske produkte na temperaturi koja se nalazi u temperaturnom rasponu od 60 do manje od 90*C.
means for obtaining layer-2 information including network information table, NIT from the signal frame, wherein the NIT includes a descriptor having the PLP identifier, an identifier of a transmission system, information for a tuning frequency of the transmission system, an active OFDM symbol duration field and a guard interval field, and means for obtaining the PLP identified by the PLP identifier in the layer-1 information and the data slice identified by the data slice identifier in the layer-1 information, wherein the PLP is mapped to a transport stream using the PLP identifier, the identifier of the transmission system, the information for a tuning frequency of the transmission system, the active OFDM symbol duration field and the guard interval field in the descriptor in the NIT; 
sredstva (1803) za dobivanje NIT uključujući identifikator PLP-a (PLP_id) i identifikator sustava prijenosa (transmission_system_id) iz sloj 2, L2 informacije okvira signala, i dobivanje PLP-a koji odgovara identifikatoru PLP-a i identifikatoru sustava prijenosa uključenog u NIT; i sredstva (1804) za dobivanje prijenosnog toka prema kojem je PLP mapiran, gdje deskriptor dostavnog sustava prijenosa uključujući identifikator PLP-a, identifikator sustava prijenosa i zaštitna intervalna polja u TS petlji NIT mapa prenose tokove do PLP-ova u podatkovnim komadima sustava prijenosa.
Further embodiments of the invention are as follows: 
Datum objave europskog patenta:
B represents a -V-carbocyclic group or a -W-heterocyclyl group wherein said carbocyclic and heterocyclyl groups may be optionally substituted by one or more (e.g. 
B predstavlja -V-karbocikličnu grupu ili -W-heterociklil grupu, pri čemu spomenute karbociklične i heterociklil grupe mogu biti opcionalno supstituirane sa jednom ili više (npr.
• peripheral arterial disease; peripheral occlusive arterial disease; peripheral vascular disease; hypertonias; Raynaud's syndrome or phenomenon; critical limb ischemia; vasculitis; peripheral embolism; intermittent claudication; vaso-occlusive crisis; Duchene's muscular dystrophy; Becker muscular dystrophy; microcirculation abnormalities; vascular leakage or permeability issues; 
• perifernom arterijskom bolesti; perifernom okluzivnom arterijskom bolesti; perifernom vaskularnom bolesti; hipertonijama; Raynaudovim sindromom ili fenomenom; kritičnom ishemijom ekstremiteta; vaskulitisom; perifernom embolijom; povremenim klaudiranjem; vazookluzivnom krizom; Ducheneovom mišićnom distrofijom; Beckerovom mišićnom distrofijom; abnormalnostima mikrocirkulacije; vaskularnim curenjem ili problemima s propusnosti;
Item 11. The use of any one of the preceding items, wherein the disorder is selected from neurodegenerative diseases, neuromuscular diseases, pain, lysosomal diseases, trauma, bone marrow injuries, cancers of the nervous system, demyelinating diseases, autoimmune diseases of the nervous system, neurotoxic syndromes, sleeping disorders. 
AAV vektor iz patentnog zahtjeva 3 ili patentnih zahtjeva 4 do 7 za njihov dio ovisan o patentnom zahtjevu 3, pri čemu je poremećaj odabran između neurodegenerativnih bolesti, neuromuskularnih bolesti, boli, lizosomskih bolesti, traume, ozljeda koštane srži, karcinoma živčanog sustava, demijelinizirajućih bolesti, autoimunih bolesti živčanog sustava, neurotoksičnih sindroma, poremećaja spavanja.
The graph below shows a representative figure from three independent assays. 
Dijagram dan niže prikazuje reprezentativrii sliku iz tri neovisna ispitivanja.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of Claims 1 to 7. 
In vitro metoda proizvodnje aktiviranog citotoksičnog T limfocita (CTL), metoda obuhvaća kontaktiranje CTL-a in vitro s antigenom punim ljudskih MHC molekula klase I s ekspresijom prikladne stanice koja predstavlja antigen na površini za vremensko razdoblje dovoljno za aktiviranje spomenutog CTL-a na način specifičan za antigen, pri čemu je spomenuti antigen peptid sukladno bilo kojoj od Tvrdnji 1 do 3.
Particularly, the present invention provides a compound having the structure represented by formula (I): including its free form, salt form, enantiomer, diastereomer or hydrate, wherein 
HR P20140717 T1 PATENTNI ZAHTJEVI 1. Spoj formule I: lj uključujući njegov slobodni oblik, oblik soli, stereoizomer, enantiomer, dijastereomer ili hidrat, gdje
The compound of claim 6, wherein enantiomeric excess of said compound is at least about 80%. 
Spoj prema zahtjevu 6, naznačen time, da enantiomerni višak navedenog spoja iznosi najmanje oko 80%.
fluoxetine, fluvoxamine, paroxetine, sertraline or escitalopram, or a pharmaceutically acceptable salt thereof; or 
(i) fluoksetin, fluvoksamin, paroksetin, sertralin ili escitalopram ili njihove farmaceutski prihvatljive soli; ili
The compound according to claim 1, wherein each —R2A7 is phenyl or naphthyl, and is optionally substituted. 
Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem od zahtjeva 1 do 25, te farmaceutski prihvatljiv nosač ili razrjeđivač.
The invention will now be described in detail, also with the aid of Examples and Figures. 
Izum će sada biti detaljno opisan, također pomoću Primjera i Slika. HR P20080682 T3
The rock bolting system as claimed in claim 3, characterized in that the expansion means (10) comprises a nipple that may be inserted into the connection unit. The rock bolting system as claimed in claim 3, wherein said abutment means comprises a flange (13). 
Sistem sidrenja u stijeni prema patentnom zahtjevu 3, naznačen time, da sredstvo, o koje se ploča uz stijenu (14) može uprijeti, jest prirubnica (13).
The heterocyclic compound or a salt thereof represented by the General Formula (1) of Claim 1 for use in the method of preventing and/or treating fibrosis and/or tumors. 
Heterociklički spoj ili njegova sol, kako je predstavljen općom formulom (1) prema zahtjevu 1, naznačen time, da se upotrebljava u postupku prevencije i/ili liječenja fibroze i/ili tumora,
PCT/CN2011/075606, filed Jun. 10, 2011, which is hereby incorporated by reference in its entirety. 
(31) Broj prve prijave: PCT/CN2011/075606 (32) Datum podnošenja prve prijave: 10.06.2011.
The method according to claim 9, wherein the obtained foamed rigid polymer product has a density of below 1 g/cm3, preferably of below 0.80 g/cm3, more preferably of below 0.75 g/cm3 and most preferably of below 0.73 g/cm3, or of 0.71 g/cm3. 
Postupak prema zahtjevu 12, naznačen time da pjenasti kruti polimerni produkt ima gustoću od manje od 1 g/em', poželjno od manje od 0.80 g/cm?, poželjnije manje od 0.75 g/em? te najpoželjnije manje od 0.73 g/em*, na primjer oko 0.71 g/em*.
Floor panel according to any of the claims 4 to 11, characterized in that the insert is held in place by means of at least the insertion of its attachment portion (50) in a recess (13) that is provided to that aim. 
Podni panel sukladno bilo kojem od zahtjeva 16 do 18, naznačen time što se element zaključavanja (12) sastoji od koekstrudirane trake sintetičkog materijala, promatrano u poprečnom presjeku, zona od sintetičkog materijala s različitim obilježjima, posebice različite fleksibilnosti.